Your search for non small cell lung cancer returned 47 results

No difference in overall survival seen with nivolumab plus ipilimumab, nivolumab alone for advanced, chemotherapy-pretreated disease

Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.

There was no improvement in overall survival with bevacizumab.

Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy, a study suggests.

Findings showed that treatment with cemiplimab-rwlc plus platinum-based chemotherapy demonstrated a statistically significant improvement in overall survival.

Drug was to be used alongside chemotherapy for patients with metastatic non-small cell lung cancer

Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.

There was an improvement in progression-free survival despite crossover.

The approval was based on data from the KEYNOTE-091 trial.

A PDUFA target date of November 24, 2022 has been set for the application.